Tumor‐infiltrating lymphocytes in colorectal cancer (CRC) predict better survival. However, associations between T‐lymphocyte count in histologically normal tissues from patients with CRC and survival remain uncertain. We examined associations of CD3+ T‐cells in colorectal tumor and histologically normal tissues with CRC‐specific and all‐cause mortality in the prospective Iowa Women's Health Study. Tissue microarrays were constructed using paraffin‐embedded colorectal tissue samples from 464 women with tumor tissues and 314 women with histologically normal tissues (55–69 years at baseline) diagnosed with incident CRC from 1986 to 2002 and followed through 2014 (median follow‐up 20.5 years). Three tumor and two histologically normal tissue cores for each patient were immunostained using CD3+ antibody and quantified, and the counts were averaged across the cores in each tissue. Cox proportional hazards regression estimated hazard ratios (HR) and 95% confidence interval (CI) for CRC‐specific and all‐cause mortality. After adjustment for age at diagnosis, body mass index, smoking status, tumor grade, and stage, HRs (95% CI) for the highest versus lowest tertile of tumor CD3+ score were 0.59 (0.38–0.89) for CRC‐specific mortality and 0.82 (0.63–1.05) for all‐cause mortality; for histologically normal CD3+ score, the corresponding HRs (95% CI) were 0.47 (0.19–1.17) and 0.50 (0.27–0.90), respectively. The CD3+ score combining the tumor and histologically normal scores was inversely associated with CRC‐specific and all‐cause mortality. Although the association between tumor CD3+ score and all‐cause mortality was not significant, both higher CD3+ T‐lymphocyte counts in tumor and histologically normal scores tended to be associated with lower CRC‐specific and all‐cause mortality.

中文翻译：

---

老年女性前瞻性队列中基于组织的 CD3+ T 淋巴细胞计数与结直肠癌存活率之间的关联

结直肠癌 (CRC) 中的肿瘤浸润淋巴细胞可预测更好的存活率。然而，结直肠癌患者组织学正常组织中 T 淋巴细胞计数与生存率之间的关联仍不确定。我们在前瞻性爱荷华妇女健康研究中检查了结直肠肿瘤和组织学正常组织中 CD3+ T 细胞与 CRC 特异性和全因死亡率的关联。使用石蜡包埋的结直肠组织样本构建了组织微阵列，这些样本来自 464 名具有肿瘤组织的女性和 314 名具有组织学正常组织的女性（基线 55-69 岁），这些女性在 1986 年至 2002 年间被诊断患有 CRC，并随访至 2014 年（中位随访时间为 20.5年）。使用 CD3+ 抗体对每位患者的三个肿瘤和两个组织学正常的组织核心进行免疫染色并定量，并且计数在每个组织中的核心上取平均值。Cox 比例风险回归估计了 CRC 特异性和全因死亡率的风险比 (HR) 和 95% 置信区间 (CI)。在调整诊断年龄、体重指数、吸烟状况、肿瘤分级和分期后，肿瘤 CD3+ 评分最高与最低三分位数的 HR（95% CI）对于 CRC 特异性死亡率分别为 0.59（0.38-0.89）和 0.82 (0.63–1.05) 全因死亡率；对于组织学正常的 CD3+ 评分，相应的 HR (95% CI) 分别为 0.47 (0.19–1.17) 和 0.50 (0.27–0.90)。CD3+ 评分结合肿瘤和组织学正常评分与 CRC 特异性和全因死亡率呈负相关。尽管肿瘤 CD3+ 评分与全因死亡率之间的关联不显着，